PPTA Statements

PPTA Statement on Safety of Plasma Protein Therapies and the H5N1 Virus es

PPTA members are committed to providing safe and effective therapies and PPTA understands that patients who rely on plasma protein therapies may have concerns about the possible transmission of highly virulent strains of influenza H5N1 viruses through these therapies. Therefore, PPTA members continue to work to ensure that these viruses or any other emerging disease, do not compromise the safety of plasma protein therapies.

Continue reading

  • Created on .

Statement on Update on Safety of Albumin

[FDA Blood Products Advisory Committee: July 21, 2005]

The Plasma Protein Therapeutics Association (PPTA) appreciates actions taken by the FDA and the Blood Products Advisory Committee (BPAC) with respect to the safety of albumin.

Continue reading

  • Created on .

PPTA Statement on Review of Donor Weight Loss Monitoring

[FDA Blood Products Advisory Committee: October 21-22, 2004]

The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world's major producers of plasma-derived and recombinant analog therapies.

Continue reading

  • Created on .
Copyright © 2020 PPTA. All rights reserved. (202) 789-3100